U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Oligoprogression

MedGen UID:
1690214
•Concept ID:
C5205436
•
Pathologic Function
Synonym: Oligoprogressive

Definition

Disease progression at a limited number of anatomic sites, in the context of stable disease at other anatomic sites. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVOligoprogression

Professional guidelines

PubMed

Treatment Landscape of Renal Cell Carcinoma.
Chen YW, Wang L, Panian J, Dhanji S, Derweesh I, Rose B, Bagrodia A, McKay RR
Curr Treat Options Oncol 2023 Dec;24(12):1889-1916. Epub 2023 Dec 28 doi: 10.1007/s11864-023-01161-5. PMID: 38153686Free PMC Article
Challenging conventional Superior Vena Cava (SVC) syndrome treatment.
Dabo-Trubelja A
Ann Palliat Med 2023 Jul;12(4):662-664. Epub 2023 Feb 20 doi: 10.21037/apm-22-1451. PMID: 37038069
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation.
Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, Dingemans AC, Fournier B, Hurkmans C, Lecouvet FE, Meattini I, Méndez Romero A, Ricardi U, Russell NS, Schanne DH, Scorsetti M, Tombal B, Verellen D, Verfaillie C, Ost P
Lancet Oncol 2020 Jan;21(1):e18-e28. doi: 10.1016/S1470-2045(19)30718-1. PMID: 31908301

Recent clinical studies

Etiology

Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs.
Wu L, Zou Z, Li Y, Hao X, Ying J, Li J, Xing P
J Transl Med 2024 Jun 20;22(1):585. doi: 10.1186/s12967-024-05388-0. PMID: 38902768Free PMC Article
Treatment Landscape of Renal Cell Carcinoma.
Chen YW, Wang L, Panian J, Dhanji S, Derweesh I, Rose B, Bagrodia A, McKay RR
Curr Treat Options Oncol 2023 Dec;24(12):1889-1916. Epub 2023 Dec 28 doi: 10.1007/s11864-023-01161-5. PMID: 38153686Free PMC Article
Incorporating Stereotactic Ablative Radiotherapy into the Multidisciplinary Management of Renal Cell Carcinoma.
Raj RK, Upadhyay R, Wang SJ, Singer EA, Dason S
Curr Oncol 2023 Dec 1;30(12):10283-10298. doi: 10.3390/curroncol30120749. PMID: 38132383Free PMC Article
Efficacy of rechallenge immunotherapy after immune monotherapy resistance in patients with advanced non-small cell lung cancer.
Xu M, Hao Y, Shi Z, Song Z
J Cancer Res Clin Oncol 2023 Dec;149(20):17987-17995. Epub 2023 Nov 17 doi: 10.1007/s00432-023-05490-8. PMID: 37975902
Systemic therapy de-escalation in advanced ovarian cancer: a new era on the horizon?
Caruso G, Coleman RL, Aletti G, Multinu F, Botticelli A, Palaia I, Cliby W, Colombo N
Int J Gynecol Cancer 2023 Sep 4;33(9):1448-1457. doi: 10.1136/ijgc-2023-004740. PMID: 37597852

Diagnosis

Locoregional Therapies for Primary and Metastatic Breast Cancer: AJR Expert Panel Narrative Review.
Deipolyi AR, Ward RC, Riaz A, Vogl TJ, Simmons RM, Pieper CC, Bryce Y
AJR Am J Roentgenol 2024 Feb;222(2):e2329454. Epub 2023 Jun 28 doi: 10.2214/AJR.23.29454. PMID: 37377360
Treatment Landscape of Renal Cell Carcinoma.
Chen YW, Wang L, Panian J, Dhanji S, Derweesh I, Rose B, Bagrodia A, McKay RR
Curr Treat Options Oncol 2023 Dec;24(12):1889-1916. Epub 2023 Dec 28 doi: 10.1007/s11864-023-01161-5. PMID: 38153686Free PMC Article
Incorporating Stereotactic Ablative Radiotherapy into the Multidisciplinary Management of Renal Cell Carcinoma.
Raj RK, Upadhyay R, Wang SJ, Singer EA, Dason S
Curr Oncol 2023 Dec 1;30(12):10283-10298. doi: 10.3390/curroncol30120749. PMID: 38132383Free PMC Article
Local Ablative Therapies for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.
Jairam V, Park HS, Decker RH
Cancer J 2020 Mar/Apr;26(2):129-136. doi: 10.1097/PPO.0000000000000433. PMID: 32205537
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation.
Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, Dingemans AC, Fournier B, Hurkmans C, Lecouvet FE, Meattini I, Méndez Romero A, Ricardi U, Russell NS, Schanne DH, Scorsetti M, Tombal B, Verellen D, Verfaillie C, Ost P
Lancet Oncol 2020 Jan;21(1):e18-e28. doi: 10.1016/S1470-2045(19)30718-1. PMID: 31908301

Therapy

What to do after immune-checkpoint inhibitors failure in advanced non-small cell lung cancer: an expert opinion and review.
Agostara AG, Roazzi L, Villa F, Romano' R, Piscazzi D, Martinelli F, Ciarlo G, Oresti S, Travaglini F, Marando A, Sartore-Bianchi A, Giannetta L, Cerea G, Siena S, Pizzutilo EG, Signorelli D
Expert Rev Respir Med 2023 Jul-Dec;17(9):787-803. Epub 2023 Oct 27 doi: 10.1080/17476348.2023.2268509. PMID: 37817448
Management of oligoprogression in non-small cell lung cancer patients.
Tartarone A, Lerose R, Tartarone M
Med Oncol 2022 Feb 12;39(5):56. doi: 10.1007/s12032-022-01666-3. PMID: 35150371
Management of Oligometastasis and Oligoprogression in Patients with Epidermal Growth Factor Receptor Mutation-Positive NSCLC in the Era of Third-Generation Tyrosine Kinase Inhibitors.
Lim JU
Clin Lung Cancer 2021 Sep;22(5):e786-e792. Epub 2021 Mar 16 doi: 10.1016/j.cllc.2021.03.004. PMID: 33849807
Local Ablative Therapies for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.
Jairam V, Park HS, Decker RH
Cancer J 2020 Mar/Apr;26(2):129-136. doi: 10.1097/PPO.0000000000000433. PMID: 32205537
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation.
Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, Dingemans AC, Fournier B, Hurkmans C, Lecouvet FE, Meattini I, Méndez Romero A, Ricardi U, Russell NS, Schanne DH, Scorsetti M, Tombal B, Verellen D, Verfaillie C, Ost P
Lancet Oncol 2020 Jan;21(1):e18-e28. doi: 10.1016/S1470-2045(19)30718-1. PMID: 31908301

Prognosis

Treatment Landscape of Renal Cell Carcinoma.
Chen YW, Wang L, Panian J, Dhanji S, Derweesh I, Rose B, Bagrodia A, McKay RR
Curr Treat Options Oncol 2023 Dec;24(12):1889-1916. Epub 2023 Dec 28 doi: 10.1007/s11864-023-01161-5. PMID: 38153686Free PMC Article
Systemic therapy de-escalation in advanced ovarian cancer: a new era on the horizon?
Caruso G, Coleman RL, Aletti G, Multinu F, Botticelli A, Palaia I, Cliby W, Colombo N
Int J Gynecol Cancer 2023 Sep 4;33(9):1448-1457. doi: 10.1136/ijgc-2023-004740. PMID: 37597852
Image-guided thermal ablation for patients with epidermal growth factor receptor-mutant nonsmall cell lung cancer.
Huang Y, Kong Y, Wei Z, Ye X
Asia Pac J Clin Oncol 2023 Aug;19(4):427-433. Epub 2022 Dec 8 doi: 10.1111/ajco.13875. PMID: 36480416
Radiogenomics in Interventional Oncology.
Moussa AM, Ziv E
Curr Oncol Rep 2021 Jan 2;23(1):9. doi: 10.1007/s11912-020-00994-9. PMID: 33387095
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation.
Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, Dingemans AC, Fournier B, Hurkmans C, Lecouvet FE, Meattini I, Méndez Romero A, Ricardi U, Russell NS, Schanne DH, Scorsetti M, Tombal B, Verellen D, Verfaillie C, Ost P
Lancet Oncol 2020 Jan;21(1):e18-e28. doi: 10.1016/S1470-2045(19)30718-1. PMID: 31908301

Clinical prediction guides

Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.
Tsai CJ, Yang JT, Shaverdian N, Patel J, Shepherd AF, Eng J, Guttmann D, Yeh R, Gelblum DY, Namakydoust A, Preeshagul I, Modi S, Seidman A, Traina T, Drullinsky P, Flynn J, Zhang Z, Rimner A, Gillespie EF, Gomez DR, Lee NY, Berger M, Robson ME, Reis-Filho JS, Riaz N, Rudin CM, Powell SN; CURB Study Group
Lancet 2024 Jan 13;403(10422):171-182. Epub 2023 Dec 14 doi: 10.1016/S0140-6736(23)01857-3. PMID: 38104577Free PMC Article
Treatment Landscape of Renal Cell Carcinoma.
Chen YW, Wang L, Panian J, Dhanji S, Derweesh I, Rose B, Bagrodia A, McKay RR
Curr Treat Options Oncol 2023 Dec;24(12):1889-1916. Epub 2023 Dec 28 doi: 10.1007/s11864-023-01161-5. PMID: 38153686Free PMC Article
Efficacy of rechallenge immunotherapy after immune monotherapy resistance in patients with advanced non-small cell lung cancer.
Xu M, Hao Y, Shi Z, Song Z
J Cancer Res Clin Oncol 2023 Dec;149(20):17987-17995. Epub 2023 Nov 17 doi: 10.1007/s00432-023-05490-8. PMID: 37975902
Integrating stereotactic body radiation therapy (SBRT) and systemic treatments in oligoprogressive prostate cancer: new evidence from the literature.
Francolini G, Loi M, Detti B, Desideri I, Mangoni M, Simontacchi G, Meattini I, Livi L
Clin Exp Metastasis 2021 Apr;38(2):227-230. Epub 2021 Jan 20 doi: 10.1007/s10585-021-10072-4. PMID: 33471291
Radiogenomics in Interventional Oncology.
Moussa AM, Ziv E
Curr Oncol Rep 2021 Jan 2;23(1):9. doi: 10.1007/s11912-020-00994-9. PMID: 33387095

Recent systematic reviews

Stereotactic ablative radiotherapy for oligoprogressive solid tumours: A systematic review and meta-analysis.
Tan VS, Padayachee J, Rodrigues GB, Navarro I, Shah PS, Palma DA, Barry A, Fazelzad R, Raphael J, Helou J
Radiother Oncol 2024 Nov;200:110505. Epub 2024 Aug 26 doi: 10.1016/j.radonc.2024.110505. PMID: 39197501
Systematic review of the efficacy of stereotactic ablative radiotherapy for oligoprogressive disease in metastatic cancer.
Doyle E, Killean AJ, Harrow S, Phillips ID
Radiother Oncol 2024 Jul;196:110288. Epub 2024 Apr 20 doi: 10.1016/j.radonc.2024.110288. PMID: 38648995
The Effectiveness and Safety of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Oligoprogressive Breast Cancer: A Systematic Review.
Yan B, Ramadan S, Jerzak KJ, Louie AV, Donovan E
Curr Oncol 2023 Jul 21;30(7):6976-6985. doi: 10.3390/curroncol30070505. PMID: 37504365Free PMC Article
Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty.
Bamias A, Stenzl A, Brown SL, Albiges L, Babjuk M, Birtle A, Briganti A, Burger M, Choudhury A, Colecchia M, De Santis M, Fanti S, Fonteyne V, Gallucci M, Rivas JG, Huddart R, Junker K, Kroeze S, Loriot Y, Merseburger A, Montironi R, Necchi A, Oing C, Oldenburg J, Ost P, Pinkawa M, Ribal MJ, Rouprêt M, Thoeny H, Zilli T, Hoskin P
Eur Urol 2023 Oct;84(4):381-389. Epub 2023 May 20 doi: 10.1016/j.eururo.2023.05.005. PMID: 37217391
Local Therapy for Oligoprogressive Disease: A Systematic Review of Prospective Trials.
Kim H, Venkatesulu BP, McMillan MT, Verma V, Lin SH, Chang JY, Welsh JW
Int J Radiat Oncol Biol Phys 2022 Nov 15;114(4):676-683. Epub 2022 Aug 13 doi: 10.1016/j.ijrobp.2022.08.027. PMID: 35973624

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...